- After seven days of treatment with NeoTherapeutics' flagship compound,AIT-082, rats with spinal cord injuries were found to have increased levels of cilliary neurotrophic factor and brain-derived neurotrophic factor, which have been shown to play an important part in the regeneration of spinal cord motor neurons in cell culture studies. The company says that it may begin clinical studies in this area after animal studies are completed. AIT-082 is currently in clinical trials for the treatment of Alzheimer's disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze